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accurate incidence and prevalence data, but incidence estimates were found to be 
5-12 people/million/year in US. AL amyloidosis is associated with early mortality 
(median survival < 3 years in many series) and a 42-64% rate of non-response or 
progression. Costly complications of AL amyloidosis include disease-related organ 
failure. For example, kidney involvement is present in about 70% of patients, and 
rates of dialysis in patients with AL amyloidosis range from 5-18% with mean total 
12-month healthcare costs (inpatient, outpatient and indirect costs) for patients 
receiving dialysis being $99,776. There are no disease specific patient-reported out-
come (PROs) tools developed for AL amyloidosis, but patients report severe psycho-
logical distress, anxiety and also experience unintentional weight loss. There are 
no consistent clinical guidelines for treatment of AL amyloidosis especially after 
relapse as no drug has received FDA or EMA approval for this indication. Overall, 
limited efficacy and significant toxicity are still major concerns with current ther-
apy. CONCLUSIONS: Limited epidemiologic and health outcomes data exist in the 
literature for relapsed or refractory AL amyloidosis. Treatment options are insuf-
ficient. New therapies which offer better clinical outcomes with less toxicity are 
needed to improve patient care.
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OBJECTIVES: To develop consensus statements outlining the impact of endoscopic 
linear stapling device stability on potential complications of thoracic surgery and 
the stress/concern of thoracic surgeons. METHODS: An 8-member expert panel 
of practicing thoracic surgeons representing eight different countries participated 
in a Delphi panel process that included two anonymous surveys. The first survey 
included binary, multiple-response, and Likert scale type questions, which were 
then converted into affirmative statements for the second survey if an adequate 
number of respondents answered similarly. Consensus was defined a priori when 
≥ 70% of respondents agreed with the affirmative statement in survey 2. RESULTS: 
All 8 panelists (100%) completed surveys 1 and 2. Panelists unanimously agreed an 
endoscopic linear stapling device with improved stability would result in less stress/
concern for critical firings, surgeries where a fellow is being trained, and robot-
assisted surgeries requiring an assistant. Across all tissue types, all panelists agreed 
that reduced unintentional tissue/structure damage and reduced tension on tissue 
being fired upon may result from use of an endoscopic linear stapling device that 
provides improvement in stability. The panel unanimously considered endoscopic 
linear stapling device stability to have more clinical importance in VATS thoracic 
surgery compared to open thoracic surgery. CONCLUSIONS: Improved endoscopic 
linear stapling device stability is a critical component of thoracic surgery that is 
likely to result in more frequent positive surgical outcomes when compared to a 
device with greater instability.
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OBJECTIVES: Brazil and Mexico present an attractive opportunity for biosimilar 
manufacturers. The majority of patients in these key Latin American markets rely 
entirely on government-sponsored healthcare. These public healthcare systems 
continually strive to limit any premium costs in favor of increasing their subopti-
mal coverage, particularly of biologics for oncology. This study explores the expected 
impact of more cost-effective biosimilar alternatives on coverage and prescribing for 
key oncology indications in Brazil and Mexico. METHODS: Across Brazil and Mexico, 
100 medical oncologists and 60 hematologists were surveyed regarding their views 
on biosimilars for breast cancer, colorectal cancer, and Non-Hodgkin’s lymphoma, 
and on current and expected biologics prescribing patterns. Additionally, 8 payers 
who influence reimbursement at a national or regional/institutional level were inter-
viewed. RESULTS: Up to 41% of biologics-eligible public patients with a given tumor 
type do not currently receive a biologic, according to surveyed physicians in Brazil and 
Mexico. Respondents largely attributed low access to limited coverage for oncology 
biologics. Surveyed physicians and interviewed payers anticipate improved access 
to biologics upon biosimilar launch and an overall reduced burden from oncology 
biologics to the healthcare systems. Although surveyed specialists indicate some 
initial caution regarding the bioequivalence of biosimilars, they nevertheless fore-
see widespread biosimilar uptake. In Brazil’s public sector, for example, respondents 
expect that 70% of Herceptin-eligible breast cancer patients will receive biosimi-
lar trastuzumab. CONCLUSIONS: Oncology biosimilars should find fertile terrain 
in Brazil and Mexico. Automatic substitution in the public sector is likely, although 
interchangeability regulations are currently under discussion in both markets. Cost-
effectiveness combined with pharmacovigilance and robust long-term safety data 
will play a major role in the continuous uptake of biosimilars versus brands, with the 
latter securing reasonable market share only if priced competitively.
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OBJECTIVES: The breakthrough therapy designation (BTD) pathway aims to expedite 
approval of drugs for serious and life-threatening conditions. BTD has been awarded 
to numerous oncology agents in development. This study assessed the likely impact 
of BTD on payer and prescriber perceptions of novel therapies, and its potential to 
cost and/or insufficient clinical advantage over other therapies. Interviewed EU5 
payers, meanwhile, demand robust demonstration of improvement over existing 
agents for favorable health technology assessment (HTA) of personalized therapies, 
and increasingly seek cost-sharing schemes. However, most surveyed US and EU5 
oncologists preferentially prescribe biomarker-driven agents where appropriate (e.g. 
80% of US respondents most frequently use crizotinib first-line for ALK-positive 
NSCLC), despite prior authorization and reauthorization being commonly required 
in the US, and country-specific cost-containment measures (e.g. physician budgets 
in Germany and prescribing monitoring registries in Italy) being key prescribing 
hurdles in the EU5. CONCLUSIONS: Strong, demonstrable advantages over existing 
agents and pricing compromises are required to secure favorable reimbursement for 
biomarker-driven treatment. While prescribers favor personalized medicine, payers 
require proven value for money. Manufacturers must strive to optimize trial design 
to help convince payers to see beyond the price tag, and be prepared to balance price 
expectations with uptake potential to optimize market access.
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OBJECTIVES: To characterize the usage of Temozolomide (TMZ) in a real-world set-
ting among patients with glioblastoma. METHODS: Adult patients diagnosed with 
malignant brain cancer (ICD9-CM, 191.XX), who underwent brain-related surgery 
90 days prior to the first TMZ dose and had ≥ 24 months of continuous enrollment, 
were identified in the IMS Pharmetrics Lifelink Plus claims database. The TMZ + 
radiation subgroup was used to reflect glioblastoma patients and differentiate them 
from patients with lower-grade gliomas. Descriptive statistics were generated for 
patient demographics, insurance-related variables, co-diagnoses, concomitant 
medications, chemotherapy cycle-duration, and TMZ dose. The index date was 
defined as the first claim for TMZ, and certain variables were assessed for pre- 
and post-12 month periods. Statistical comparisons between pre- and post-index 
were performed using McNemar’s tests. RESULTS: A total of 1,126 patients met the 
inclusion criteria and the mean age was 52.7 yrs. (SD= 10.9). There was a significant 
increase in the use of concomitant medications (antianxiety, antidepressants, and 
antiemetic) as well as co-diagnoses (depression, fatigue, seizure/epilepsy, and hear-
ing loss) in the post-index period (p< 0.001). However, in this same period, corticos-
teroid and pain medication use significantly decreased as did the co-diagnoses of 
aphasia and headache (p< 0.001). TMZ mean starting dose, duration, and number 
of maintenance phase cycles was 154.4 mg (SD= 77.9), 46 days (SD= 12), and 7 cycles 
(SD= 3), respectively. Following the first dose, 73% of patients experienced a TMZ dose 
increase. CONCLUSIONS: Post-index, patients experienced a complex change in 
both concomitant medications and co-diagnoses, possibly reflecting both a decrease 
in tumor mass and side effects of the TMZ + radiation therapy. These initial findings 
warrant further investigation of TMZ as real-world standard-of-care in glioblastoma.
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OBJECTIVES: To characterize patients and treatment approaches relative to BRAF 
gene mutation testing. METHODS: An analysis of patient characteristics, diagnostic 
and treatment including BRAF testing, age, co-morbidities, number of tumor sites, 
hospital vocation and type of therapy used was conducted using the information 
included in the IMS Brogan Enhanced Tumor Study database from October 2013 to 
September 2014. RESULTS: Out of 343 stage IV melanoma patients, 239 were tested 
for BRAF mutations. 57% (136 pts.) were BRAF positive, 36% (87 pts.) BRAF negative 
and for 7% (16 pts.) results were not reported. Patients who were tested for BRAF 
tended to be less than 50 years of age (46% vs. 16%, p< 0.01), have none or only 1 
co-morbidity (87% vs. 70%, p< 0.01), have only 1 metastasis (34% vs. 45%, p< 0.05), 
and treated in an academic facility (74% vs. 50%, p< 0.01) compared to those who 
were not tested. BRAF negative patients were more often treated with ipilimumab 
compared to those who were not tested (42% vs. 10%, p< 0.01). CONCLUSIONS: 
Patients characteristics emerged as an important factor for determining diagnostic 
and treatment protocols for metastatic melanoma patients in Canada. Younger 
patients and those with more favorable disease characteristics are more likely to 
be tested for BRAF mutations and treated with ipilimumab in those without BRAF 
mutation. BRAF testing appears to be more prevalent in academic centers than in 
community hospitals.
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OBJECTIVES: To conduct a systematic literature review on relapsed or refractory AL 
amyloidosis, focusing on clinical outcomes, epidemiology, health-related quality-
of-life (HRQoL) and economic aspects. METHODS: MEDLINE and EMBASE databases 
were searched for English-language articles published in the last 10 years using 
search terms including “Primary/Systemic amyloidosis”, “epidemiology/prevalence/
incidence”, “therapeutics/drug therapy/outcome”, ”patient-reported/quality-of-
life/satisfaction and “economics/cost” etc. Search results were manually reviewed, 
and relevant studies were selected for inclusion as appropriate. Additional refer-
ences were obtained from clinical conferences and the reference lists of selected 
articles. RESULTS: 1,141 articles were initially retrieved, and 58 were included in 
the current review. Given the rare nature of the disease, it was difficult to obtain 
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OBJECTIVES: Prior to being considered for funding at a provincial level, all oncolog-
ics must first be appraised at a national level by the pan-Canadian Oncology Drug 
Review (pCODR), except in Quebec. This research aims to explore whether there 
are any differences between the speed of provincial oncologic access and whether 
this varies by provincial wealth and/or population. METHODS: All publically avail-
able provincial funding summaries were extracted from the pCODR website up 
to October 2014 from which the appraisal outcomes and dates were extracted. 
The population, GDP and GDP per capita of each province was extracted from the 
Government of Canada statistics website. Statistical comparisons were performed 
using one-way ANOVA and Student’s t-tests. RESULTS: The average delay between 
pCODR recommendations and provincial funding decisions was 8.9 months, which 
significantly varied by province (p< 0.0001), with the lowest being British Columbia 
(2.8 months) and the highest being Prince Edward Island (15.1 months). The 4 prov-
inces with populations lower than 1 million experience significantly greater delays 
to access versus the 5 provinces whose population exceeded 1 million (12.4 vs. 6.1 
months, p< 0.005). The 4 provinces whose GDP exceeds CAD75,000 million experi-
ence significantly faster time to access than the 5 provinces whose GDP is lower than 
this (5.1 vs. 12.0 months, p< 0.005). However, this relationship does not reach sig-
nificance when GDP is examined on a per capita basis (top 4 provinces: 7.2 months 
vs. 10.3 months for the bottom 5, p= 0.11). CONCLUSIONS: There are significant 
variations in time to access for oncology drugs between different provinces. This is 
significantly related to the province population and overall wealth but not wealth 
on a per person basis. Further research can define whether this reflects differences 
in provincial assessments or whether pharmaceutical companies are prioritising 
larger provinces where better market returns can potentially be realised.
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ComParINg The vaLue of a PCodr fuLL aPProvaL versus aN aPProvaL 
CoNdITIoNaL oN CosT-effeCTIveNess beINg ImProved To aN adequaTe 
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) makes recommen-
dations at a national level for oncology drugs. Drugs can only move to provincial 
consideration if they receive a pCODR “recommendation” or “recommendation 
conditional on cost-effectiveness being improved to an acceptable level”. This 
research aims to explore if pCODR deeming an oncologic to have acceptable cost-
effectiveness can affect the speed of attaining provincial access. METHODS: All 
publically available pCODR appraisal reports and provincial funding summaries up 
to 31 September 2014 were identified from which the appraisal outcomes, incre-
mental cost-effectiveness ratios (ICERs) and dates were extracted. If more than 1 
ICER was stated, the mean value was used. Statistical comparisons were performed 
using Student’s t-tests. RESULTS: pCODR submissions encompassing 34 indica-
tions were extracted. ICERs were only stated in 13/34 of these submissions. 2/13 
were pCODR-recommended, 11/13 recommended conditional on cost-effectiveness 
being improved to an acceptable level, and 0/13 rejected. There was no significant 
difference between average delay in provincial access for the submissions that 
received a full recommendation versus those that received a conditional recom-
mendation (9.3 vs 9.3 months, p= 0.49). However, the 7 drugs with an ICER above 
CAD200,000 per Quality–Adjusted Life Year (QALY) experienced significantly longer 
delays to provincial access than the 6 drugs whose ICERs fell below this level (12.3 
vs. 8.4 months, p= 0.02). CONCLUSIONS: Oncology drugs that are deemed to have 
acceptable cost-effectiveness by pCODR did not seem to attain faster provincial 
access, although this analysis was limited by the small number of positive pCODR-
recommendations with publically available ICERs. Nevertheless, oncologics with 
higher ICERs experienced significantly greater delays to provincial access. This sug-
gests that by making greater efforts to demonstrate cost-effectiveness at the level 
of pCODR, faster provincial and patent access can be obtained.
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OBJECTIVES: The Food and Drug Administration (FDA) have approved 28 onco-
logics across 37 indications on the basis of a clinical trial package lacking com-
parative Phase III data (Macaulay, ISPOR Toronto 2014). Approval was typically 
granted for indications with no therapeutic alternative where a response rate 
≥ 10% was demonstrated. This research aims to define the circumstances under 
which oncologics can obtain both regulatory approval and public reimbursement 
in Canada on this basis. METHODS: All pan-Canadian Oncology Drug (pCODR) 
final recommendations and Provincial Funding Summaries were analysed up to 
26th November 2014 and the supportive trial package and key rationale were 
extracted. RESULTS: 36 submissions were extracted. 4 were pCODR-appraised on 
the basis of single-arm Phase II trial data. 3/4 were recommended (brentuximab 
vedotin [Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma]) and 
vismodegib) with pCODR deeming randomized controlled trials (RCTs) to be not 
feasible due to very small patient numbers and there being no standard of care. All 
3 were also subject to additional restrictions to the approved label. Nevertheless, 
the incremental cost-effectiveness ratios (ICERs) generated on such data packages 
were regarded as highly uncertain; these recommendations were all conditional 
on cost-effectiveness being improved to an acceptable level. Nevertheless, within 
12 months of all these recommendations, provincial approval was attained in ≥ 5 
provinces including the largest 3 (Ontario, Alberta, and British Columbia). For the 
rejected submission (crizotinib), an RCT was deemed feasible and pCODR would 
not make a recommendation in the absence of comparative survival and quality 
of life benefits. A subsequent resubmission including Phase III data was recom-
mended. CONCLUSIONS: pCODR will recommend oncologics based on single-arm 
Phase II data for indications where RCTs are not deemed feasible but discounting 
promote market access leverage. METHODS: Across the United States, 100 medical 
and hematological oncologists and 25 managed care organization (MCO) pharmacy 
and medical directors completed online quantitative surveys to capture their views 
on BTD. RESULTS: Surveyed payers were unanimous that BTD will influence formu-
lary decisions for oncology drugs; some 40% said BTD would result in more favorable 
tier placement, while 37% expect fewer prescribing controls. However, none of our 
surveyed payers considered themselves yet very familiar with the BTD pathway. In 
contrast, one third of surveyed oncologists declared themselves to be very familiar 
with BTD. Furthermore, almost all oncologists said that BTD will affect their prescrib-
ing; almost 50% agreed that an agent with accelerated approval based on Phase II 
data and BTD will more likely be prescribed than such an agent without BTD. Notably, 
while BTD includes no guarantee of access to other regulatory pathways other than 
fast track designation, surveyed oncologists and payers often associate accelerated 
approval and priority review with BTD. CONCLUSIONS: BTD instills confidence in 
payers and prescribers, such that this accolade looks set to positively influence reim-
bursement conditions, drive uptake, and promote market access for a given agent. 
Moreover, associating BTD with accelerated approval and priority review likely further 
inspires positivity towards BTD agents. However, that payer respondents are at least 
somewhat unfamiliar with the BTD pathway must be considered. Manufacturers 
with BTD agents must formulate their market access strategy early and efficiently, 
ensuring that payers are fully aware of the benefits and advantages that secured 
this classification.
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OBJECTIVES: To capture the trends in opioid prescribing and to determine whether 
rural residency impacts opioid prescribing patterns. METHODS: We used the National 
Ambulatory Medical Care Survey (NAMCS) data available for the years 2006-2010. The 
NAMCS data is a nationally representative annual survey of the provision and utiliza-
tion of outpatient medical care services in the US. Main outcome measure was opioid 
drug prescribed. Survey weighted logistic regression models were fit to determine 
factors influencing opioid prescribing. RESULTS: Opioid prescriptions increased from 
10% in 2006 to 12% in 2010. There was an increasing trend in rural opioid prescribing 
(11% in 2006, 12% in 2007, 14% in 2008, 15% in 2009 and 2010) as compared with urban 
location (10% from 2006-2008, 12% in 2009 and 11% in 2010). Primary care physicians 
and medical professionals were more likely to prescribe opioids (13% in 2006, 12% in 
2007, 16% in 2008, 17% in 2009 and 14% in 2010) as compared with surgeons (6%, 11%, 
10%, 10%, 14% respectively). Multivariate analyses revealed that over the years, younger 
patients (35-49 and 50-64), who did not have a cancer diagnosis, and were insured by 
Medicare or other type of insurance were more likely to get opioid prescription, while 
patients seen by surgeons were less likely to get opioids. CONCLUSIONS: Our study 
poses significant implications for healthcare professionals and policy makers. Our 
study not only demonstrated that rural residents were more likely to be prescribed opi-
oids but it showed an upward trend in rural opioid prescribing which was significantly 
different from urban locations. Increased prescribing of opioids, has led to a growing 
problem of prescription drug abuse especially among rural residents. Further research 
is warranted to study the extent of over prescribing and abuse in rural communities.
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OBJECTIVES: The pan-Canadian Oncology Drug Review (pCODR) was established in 
2010 to appraise oncology drugs in order to help guide provincial reimbursement 
decision-making. pCODR is currently being transferred to Canadian Agency for Drugs 
and Technologies in Health (CADTH) offering the opportunity for reform. This research 
aims to measure the impact of this process on access to oncology drugs in Canada 
and compare this with Quebec, which does not refer to pCODR. METHODS: All pub-
lished pCODR and Institut national d’excellence en santÃ© et en services sociaux 
(INESSS, the Quebec Health Technology Assessment body) reports were identified 
alongside pCODR provincial funding summaries up to 30 September 2014 and the 
dates, decision, and key rationale were extracted. All statistical comparisons were 
made using ANOVA and t-tests. RESULTS: Most (62% [21/34]) pCODR recommen-
dations were conditional on cost-effectiveness being demonstrated (20% recom-
mended, 18% not recommended). Following pCODR recommendations, an average 
of 6.7 months from submission, there is an additional average 8.9 month delay for 
provincial funding decision-making. The time required for provincial decision making 
was no faster for drugs recommended by pCODR versus those conditional on accept-
able cost-effectiveness (9.3 vs. 9.3 months, p= 0.49). INESSS issued recommendations 
for these corresponding oncology drugs an average of only 2.1 months after pCODR, 
6.8 months before the other provinces, a difference which is statistically significant 
(p= 0.0013). CONCLUSIONS: Given that the key issue for most candidate oncologics 
facing reimbursement is cost-effectiveness, pCODR issuing large numbers of rec-
ommendations conditional on cost-effectiveness being demonstrated adds a time-
consuming step that does not speed provincial decision making. INESSS, operating 
independently to pCODR, issue recommendations significantly sooner than other 
provinces. Based on this, we recommend that acceptable pCODR cost-effectiveness 
be a mandatory requirement prior to provincial consideration or that the pCODR 
process be curtailed into just providing a clinical benefit assessment.
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